Open Access Repository
Gene editing clinical trials could slip through Australian regulatory cracks


Full text not available from this repository.
Abstract
In this column we explore the regulatory environment within which clinical trials involving new genome editing techniques are undertaken. Ostensibly, there is regulatory congestion in this area, with overlapping obligations through the national scheme for regulating gene technology, the national scheme for regulating the supply of therapeutic goods, and the human research ethics system, predominantly administered at the institutional level. In practice, however, the oversight of gene editing clinical trials is left almost entirely to human research ethics committees. Given the uncertain risks associated with such novel technologies, we conclude that it is opportune to reconsider the rigor of current Australian processes for assessing clinical trials involving gene-editing technology.
Item Type: | Article |
---|---|
Authors/Creators: | Eckstein, L and Nicol, D |
Keywords: | gene editing, CRISPR, gene technology regulation, therapeutic goods administration, human research ethics committees |
Journal or Publication Title: | Journal of Law and Medicine |
Publisher: | Thompson Reuters |
ISSN: | 1320-159X |
Copyright Information: | Copyright 2019 Thomson Reuters (Professional) Australia Limited |
Related URLs: | |
Item Statistics: | View statistics for this item |
Actions (login required)
![]() |
Item Control Page |